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OBJECTIVE — To assess the efﬁcacy of 1-h plasma glucose concentration and the metabolic
syndrome in predicting future risk of type 2 diabetes.
RESEARCH DESIGN AND METHODS — A total of 1,611 subjects from the San An-
tonio Heart Study, who were free of type 2 diabetes at baseline; who had plasma glucose and
insulinconcentrationsmeasuredattime0,30,60,and120minduringtheoralglucosetolerance
test (OGTT); and who had their diabetes status determined with an OGTT after 7–8 years of
follow-up, were evaluated. Two models, based on glucose tolerance status, 1-h plasma glucose
concentration, and presence of the metabolic syndrome, were tested in predicting the risk for
type 2 diabetes at 7–8 years of follow-up.
RESULTS — A cutoff point of 155 mg/dl for the 1-h plasma glucose concentration during the
OGTT was used to stratify subjects in each glucose tolerance group into low, intermediate, and
highriskforfuturetype2diabetes.Amodelbasedupon1-hplasmaglucoseconcentration,Adult
Treatment Panel (ATP) III criteria for the metabolic syndrome, and fasting plasma glucose,
independent of 2-h plasma glucose, performed equally well in stratifying nondiabetic subjects
into low, intermediate, and high risk for future type 2 diabetes and identiﬁed a group of normal
glucose-tolerant subjects who were at very high risk for future type 2 diabetes.
CONCLUSIONS — The plasma glucose concentration at 1 h during the OGTT is a strong
predictor of future risk for type 2 diabetes. A plasma glucose cutoff point of 155 mg/dl and the
ATPIIIcriteriaforthemetabolicsyndromecanbeusedtostratifynondiabeticsubjectsintothree
risk groups: low, intermediate, and high risk.
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C
linical trials have demonstrated that
lifestyle intervention and pharma-
cological therapy in high-risk indi-
viduals reduce the incidence of type 2
diabetes (1). Thus, reliable models for
identiﬁcation of individuals at high risk
forfuturetype2diabetesareessentialand
have important clinical implications for
intervention programs. Subjects with im-
paired glucose tolerance (IGT) are at in-
creased risk for future type 2 diabetes (2),
and the oral glucose tolerance test
(OGTT)hasbecomethestandardmethod
for identifying individuals at risk for type
2 diabetes. Indeed, all clinical trials that
have assessed strategies for type 2 diabe-
tes prevention have recruited subjects
with IGT. Although IGT subjects have in-
creased risk for type 2 diabetes, only
50% convert to type 2 diabetes within
10 years of follow-up (2), indicating that
the future risk for diabetes is not similar
among all individuals with IGT. Further-
more, in longitudinal epidemiological
studies, 40% of subjects who develop
type 2 diabetes have normal glucose tol-
erance (NGT) at baseline, indicating that
thereisapopulationofNGTsubjectswho
are at risk for future type 2 diabetes (2).
Recently, we demonstrated that subjects
with NGT, despite having relatively low
risk for type 2 diabetes, can be stratiﬁed
into low- and high-risk categories based
upon the relationship between their post-
load and fasting plasma glucose (FPG)
concentrations (3).
Several models have been proposed
toimprovethepredictiveabilityforfuture
type 2 diabetes (4–7). These models are
based upon established risk factors for
type 2 diabetes (e.g., obesity, FPG, lipid
proﬁle, and blood pressure). All of these
risk factors are components of the meta-
bolic or insulin resistance syndrome,




is a better predictor for future type 2 dia-
betes than either the FPG or 2-h plasma
glucose concentration. Furthermore, the
addition of the 1-h plasma glucose con-
centrationtoapredictionmodelbasedon
clinical parameters signiﬁcantly im-
proved the ability of the model to predict
future type 2 diabetes (9). In this study,
wehaveusedtheclassiﬁcationtreemodel
(10) to stratify the risk for future type 2
diabetes in nondiabetic subjects based
upontheir1-hplasmaglucoseconcentra-
tion during the OGTT and the Adult
Treatment Panel (ATP) III criteria for the
metabolic syndrome. We demonstrate
that a model based on the combination of
1-h plasma glucose concentration during
the OGTT and the ATP III criteria for the
metabolic syndrome improves the ability
to predict the future risk for type 2
diabetes.
RESEARCH DESIGN AND
METHODS— All subjects were par-
ticipants of the San Antonio Heart Study
(11–13),whichisapopulation-based,ep-
idemiologicalstudyoftype2diabetesand
cardiovascular disease. A total of 2,616
eligible participants, who were free of
type2diabetesatbaseline,completeda7-
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1,610 subjects had plasma glucose mea-
surements at 0, 30, 60, and 120 min dur-
ing the baseline OGTT and constitute the
study population. The study was ap-
proved by the institutional review board
of University of Texas Health Science
Center at San Antonio. All subjects gave
their written informed consent before
participation.
Deﬁnition of variables and outcomes
All studies were performed in a mobile
clinic following a 12-h overnight fast. A
standard 75-g glucose OGTT was per-
formed, and blood was obtained at 0, 30,
60, and 120 min for determination of
plasma glucose and serum insulin con-
centrations. Plasma glucose and serum
lipids were measured with an Abbott
Bichromatic Analyzer (South Pasadena,
CA). The diagnosis of diabetes was based
upon World Health Organization criteria
(14). Subjects on insulin or oral antihy-
perglycemic medications also were con-
sidered to have diabetes. The metabolic
syndrome was diagnosed according to
ATP III criteria (15).
Classiﬁcation tree
Recursively partitioned classiﬁcation
trees (16) were used to model the rela-
tionship between the future risk of type 2
diabetes and 1) 1-h plasma glucose con-
centration during the OGTT and 2) pres-
ence or absence of the metabolic
syndrome. Sequential partitioning of the
individuals based upon their 1-h plasma
glucose concentration relative to 155
mg/dl (above or below) and the presence
or absence of the metabolic syndrome
produced subgroups or compartments of
individuals with homogenous risk for fu-
ture type 2 diabetes. Subgroups with an-
nualriskforfuturetype2diabetes0.5%
(3.5% risk in 7–8 years) were consid-
ered as having low risk for future type 2
diabetes. Annual risk between 1 and 2%
(7–15%riskin7–8years)wasconsidered
intermediate risk. Annual risk 4%
(30% risk in 7–8 years) was considered
high risk.
Statistical methods
Variables are presented as the means 
SD. The signiﬁcance of the mean differ-
ences was tested with ANOVA. Differ-
ences between categorical variables were
tested with the 
2 test. Statistical signiﬁ-
cance was considered at the level of P 
0.05. Assessment of the predictive dis-
crimination of the various models was
made using the receiver-operating char-
acteristic curve by plotting the sensitivity
against the corresponding false-positive
rate. Statistical analysis was performed
with the SPSS software package.
RESULTS— Table 1 presents the an-
thropometric, laboratory, and clinical
characteristicsofthestudypopulation.Of
1,611 study participants, 1,301 had
NGT, 90 had impaired fasting glucose
(IFG), and 221 had IGT at baseline, re-
spectively. Fifty-one of 221 subjects with
IGT also had IFG and were designated as
having combined glucose intolerance
(CGI). The conversion rate to type 2 dia-
betes over the study period (7–8 years)
was 5.0, 26.1, 30.9, and 82.3% for NGT,
IFG, IGT, and CGI subjects, respectively.
We previously demonstrated that the 1-h
plasma glucose concentration during the
OGTT is a good predictor for future type
2 diabetes (9). A plasma glucose cutoff
point of 155 mg/dl has the maximal sum
of sensitivity and speciﬁcity (0.75 and
0.79forsensitivityandspeciﬁcity,respec-
tively) and for predicting future type 2
diabetes. Similarly, the ideal cutoff point
for fasting plasma glucose concentration
in predicting future type 2 diabetes was
94.5 mg/dl. Therefore, we have used
these values as cutoff points to test the
prediction of future type 2 diabetes with
two tree models.
The ﬁrst tree model is based upon the
glucose tolerance status (17), 1-h plasma
glucose value, and presence of the meta-
bolic syndrome. The receiver-operating
characteristic for this model was 86.7%.
In this model, individuals were divided,
accordingtotheAmericanDiabetesAsso-
ciation criteria (17), into four groups
(NGT, IFG, IGT, and CGI) based upon
their fasting and 2-h plasma glucose con-
centration. Individuals in each group
were further divided into two subgroups
basedupontheir1-hplasmaglucosecon-
centration (above or below 155 mg/dl).
Figure 1 depicts the incidence of type 2
diabetes based upon 1-h plasma glucose
concentration.Although,asawhole,sub-
jects with NGT had a low risk for type 2
diabetes (5.0%), normal glucose-tolerant
subjects with 1-h plasma glucose 155
mg/dl had signiﬁcantly increased risk
(15.3%) for future type 2 diabetes com-
pared with nor subjects with 1-h plasma
glucose 155 mg/dl (2.9%) (P 
0.0001). Further division of this group
baseduponthepresenceorabsenceofthe
metabolic syndrome demonstrated that
NGT subjects with 1-h plasma glucose
155 mg/dl and the metabolic syndrome
had a 32.1% incidence rate of type 2 dia-
betes compared with a 9.4% incidence
rate for subjects without the metabolic
syndrome.
Subjects with IFG and a 1-h plasma
glucose 155 mg/dl had a 37.3% inci-
dence of type 2 diabetes, while IFG sub-
jects with a 1-h plasma glucose
concentration 155 mg/dl had a 10.8%
incidence rate. Table 2 presents the odds
Table 1—Anthropometric, clinical, and laboratory characteristics of the study population
NGT IFG IGT CGI ANOVA
n 1,301 90 169 51
Sex (% female) 57 39 63 53 0.0001
Age (years) 42  11 47  10 49  10 51  2 0.0001
BMI (kg/m
2) 27.1  5.1 29.8  5.9 30.3  5.6 31.1  0.8 0.0001
Waist circumference (cm) 87.9  1.3 96.3  1.2 96.4  1.6 102.5  1.8 0.0001
FPG (mg/dl) 83  8 106  59 3  12 109  1 0.0001
2-h plasma glucose (mg/dl) 95  23 105  22 165  16 173  5 0.0001
Subjects with 1-h plasma glucose  155 mg/dl 217 52 171 50 0.0001
Metabolic syndrome (%) 14.3 66.7 49.3 84.3 0.0001
Subjects converted to diabetes 65 23 52 42 0.0001
Data are means  SD, unless otherwise indicated.
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glucose tolerance groups. Subjects with
IGT and a 1-h plasma glucose 155
mg/dl had a 35.5% diabetes incidence
rate,whileIGTsubjectswitha1-hplasma
glucose 155 mg/dl had a 17.8% diabe-
tes incidence rate.
The second model includes the 1-h
plasma glucose concentration, the meta-
bolic syndrome, and fasting plasma glu-
cose concentration. The receiver-
operating characteristic for this model
was 85.4%. In this model, subjects were
divided into two groups based upon their
1-h plasma glucose concentration (above
or below 155 mg/dl) and each group was
further divided into two subgroups based
upon the presence or absence of the met-
abolic syndrome. Figure 2 depicts the 7-
to 8-year risk for type 2 diabetes for each
subgroup. In general, nondiabetic sub-
jects with 1-h plasma glucose 155
mg/dl had a low risk (3.9%) for future
developmentoftype2diabetescompared
with subjects with a 1-h plasma glucose
155 mg/dl (31.0%) (P  0.0001).
When subjects with 1-h plasma glucose
155 mg/dl were divided according to
the presence or absence of the metabolic
syndrome, subjects with a 1-h plasma
glucose 155 mg/dl without the meta-
bolicsyndromehada3.2%riskforfuture
type 2 diabetes, while those with the met-
abolic syndrome had 7.8% risk for future
diabetes. Subjects with a 1-h plasma glu-
cose concentration 155 mg/dl and the
metabolic syndrome had a 51.6% risk for
future diabetes. Subjects with a 1-h
plasma glucose 155 mg/dl without the
metabolic syndrome, but with a fasting
plasma glucose 95 mg/dl, had a 44.7%
risk for future diabetes, while subjects
with a 1-h plasma glucose 155 mg/dl
withoutthemetabolicsyndromeandfast-
ing plasma glucose 95 mg/dl had a
10.8% risk for future type 2 diabetes.
Because the waist circumference is
rarely measured in clinical practice and is
part of the ATP III deﬁnition of the meta-
bolic syndrome, we also examined the
predictive value of triglyceride–to–HDL
cholesterolratio3.5inplaceofthemet-
abolic syndrome (Table 2). Although the
metabolic syndrome was a better predic-
tor compared with the triglycerides–to–
HDL cholesterol ratio, a model based on
1-hplasmaglucoseconcentrationandtri-
glyceride–to–HDL cholesterol ratio could
classify subjects to three risk groups: low,
intermediate, and high risk (Table 2).
CONCLUSIONS — The American
Diabetes Association Consensus State-
ment has recommended metformin, in
addition to diet and exercise, in individ-
uals with IGT/IFG to reduce their risk for
future diabetes (18). This recommenda-
tion for pharmacologic intervention un-
derscores the need for models that
reliably identify individuals at increased
risk for future development of type 2
diabetes.Theresultsofthisstudydemon-
strate that the plasma glucose concentra-
tion at 1 h during the OGTT is a useful
tool that can be used to stratify the risk of
future type 2 diabetes into three groups:
low, intermediate, and high risk. In gen-
eral, subjects with NGT have low risk for
progression to type 2 diabetes (0.67%
annualrate)(2).However,40%ofindi-
viduals who develop type 2 diabetes have
NGT at baseline (2) and, in the present
study, 16.7% of normal glucose-tolerant
subjects with a 1-h plasma glucose con-
centration (OGTT) 155 mg/dl devel-
oped type 2 diabetes over a 7- to 8-year
period. In this group of normal glucose-
tolerant subjects, the annual risk for fu-
ture type 2 diabetes was signiﬁcantly
greater (2.2% per year) compared with
Figure 1— Tree model based on the glucose tolerance status of the subjects, 1-h plasma glucose
concentration, and presence or absence of the metabolic syndrome. The numbers in each nodule
representthenumberofsubjectsconvertingtodiabetes/totalnumberofsubjectsineachparticular
group and the incidence rate of conversion to diabetes over 8 years. 1-h PG, 1-h plasma glucose
concentration during the OGTT; MS, metabolic syndrome present; MS, metabolic syndrome
absent.
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centration did not exceed 155 mg/dl
(0.39% per year, P  0.00001). Further,
NGT subjects with a 1-h plasma glucose
155 mg/dl who fulﬁlled the ATP III cri-
teria for the metabolic syndrome had a
4.3% annual risk for future type 2 diabe-
tes. Thus, the group of normal glucose-
tolerantsubjectswith1-hPG155mg/dl
plus the metabolic syndrome is at very
high risk for the development of type 2
diabetes, their risk exceeds that of sub-
jectswithIFGorIGT,andtheiroddsratio
for developing diabetes is double that of
IGT subjects with a 1-h plasma glucose
155 mg/dl (Table 2). Consistent with
the American Diabetes Association Con-




apy (metformin) to reduce future risk for
diabetes.
Subjects with CGI have the greatest
risk for future type 2 diabetes, with an
annual risk 10% per year, while sub-
jects with isolated IFG or IGT have an
intermediate risk between CGI and NGT.
However,withintheIFGandIGTgroups,
the 1-h plasma glucose during the OGTT
also stratiﬁes the future diabetes risk into
intermediateandhighrisk.Thus,IFGand
IGT subjects with a 1-h plasma glucose
155 mg/dl have an annual risk of
1.5% compared with an annual risk of
5% for IGT and IFG subjects with a 1-h
plasma glucose 155 mg/dl. It is note-
worthy that every CGI subject had a 1-h
plasma glucose concentration 155 mg/
dl. Thus, the plasma glucose concentra-
tion at 1 h during the OGTT is a strong
predictor for future type 2 diabetes, inde-
pendent of the glucose tolerance status,
and a 155 mg/dl cutoff point divides in-
dividuals with NGT, IFG, and IGT into
low-, intermediate-, and high-risk
groups.
A predictive model based on the
plasma glucose concentration at 1 h dur-
ing the OGTT and the presence or ab-
sence of the metabolic syndrome,
independent of the 2-h plasma glucose
concentration, performs equally well in
stratifying subjects for future risk of type
2 diabetes compared with the model that
includes the 2-h plasma glucose concen-
tration. The earlier model had 0.82 sensi-
tivity and 0.63 speciﬁcity compared with
0.82 and 0.67 sensitivity and speciﬁcity,
respectively, for the model based on 1-h
plasma glucose concentration. Moreover,
Figure 2— Tree model based on 1-h plasma glucose (PG) concentration, presence or absence of
the metabolic syndrome, and fasting plasma glucose concentration. The numbers in each nodule
representthenumberofsubjectsconvertingtodiabetes/totalnumberofsubjectsineachparticular
group and the incidence rate of conversion to diabetes over 8 years. 1-h PG, 1-h plasma glucose
concentration during the OGTT; MS, metabolic syndrome present; MS, metabolic syndrome
absent.
Table 2—Odds ratio and 95% CI for the risk of developing type 2 diabetes for the prediction
models
Odds ratio (95% CI)
Model 1
NGT, 1-h plasma glucose 155 mg/dl 1
NGT, 1-h plasma glucose 155 mg/dl without metabolic
syndrome
3.4 (1.8–6.4)
NGT, 1-h plasma glucose 155 mg/dl with metabolic
syndrome
15.2 (7.8–29.3)
IFG, 1-h plasma glucose 155 mg/dl 4.0 (1.3–11.9)
IFG, 1-h plasma glucose 155 mg/dl 19.5 (10.0–38.0)
IGT, 1-h plasma glucose 155 mg/dl 7.1 (3.0–16.5)
IGT, 1-h plasma glucose 155 mg/dl 18.1 (10.8–30.1)
Model 2(A)
1-h plasma glucose 155 mg/dl without metabolic syndrome 1
1-h plasma glucose 155 mg/dl with metabolic syndrome 2.4 (1.2–4.8)
1-h plasma glucose 155 mg/dl without metabolic syndrome
and FPG 95 mg/dl
3.6 (2.0–6.2)




1-h plasma glucose 155 mg/dl and triglyceride–to–HDL
cholesterol ratio 3.5
1
1-h plasma glucose  155 mg/dl and triglyceride–to–HDL
cholesterol ratio 3.5
2.3 (1.3–4.2)
1-h plasma glucose 155 mg/dl and triglyceride–to–HDL
cholesterol ratio 3.5 and FPG 95 mg/dl
4.3 (2.4–7.9)
1-h plasma glucose 155 mg/dl and triglyceride–to–HDL
cholesterol ratio 3.9 or FPG 95 mg/dl
22.4 (14.2–35.3)
Abdul-Ghani and Associates
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plasmaglucose155mg/dlplusthemet-
abolic syndrome or FPG 95 mg/dl) re-
duces the number of subjects in the very-
high-risk group (6.5% incidence per
year), who are candidates for pharmaco-
logical intervention, from 18% (based on
the model that includes the 2-h plasma
glucoseconcentration)to14%ofthetotal
study population. Furthermore, the
model with the 1-h plasma glucose con-
centration plus the metabolic syndrome
performs better in predicting future dia-
betes than does the American Diabetes
Association criteria of IGT or IFG. Most
importantly, 17% of normal glucose-
tolerant subjects, who have intermediate
and high risk for future type 2 diabetes
and who were identiﬁed with the 1-h
plasmaglucoseplusmetabolicsyndrome,
would have been missed with the Ameri-
can Diabetes Association criteria alone.
These observations underscore the im-
portance of obtaining the plasma glucose
concentration at 1 h during the OGTT.
Substituting the metabolic syndrome
with the triglyceride–to–HDL cholesterol
ratio in the second model slightly reduces
its predictability. However, the second
modelwiththetriglyceride–to–HDLcho-
lesterolratioisagoodpredictorforfuture
risk of type 2 diabetes and classiﬁes sub-
jects into three risk groups. Because mea-
surement of triglyceride and HDL
cholesterol is part of the routine clinical
practice, the second model could be used
in routine clinical practice to assess the
riskofnondiabeticsubjectsforfuturerisk
of type 2 diabetes.
Why is the 1-h plasma glucose con-
centration a better predictor for future
type 2 diabetes than the 2-h plasma glu-
cose?Itcouldbearguedthatthehighpre-
dictabilityfor1-hplasmaglucoseisdueto
its high correlation with the 2-h plasma
glucose(r0.58,P0.0001).However,
the 1-h plasma glucose stratiﬁes subjects
with NGT, as well as subjects with IGT,
into two risk groups, high and low. Thus,
it is unlikely that its predictability is sec-
ondary to its correlation with the 2-h
plasma glucose. Subjects who are des-
tined to develop type 2 diabetes manifest
two major defects: 1) insulin resistance in
liver and skeletal muscle and 2) impaired
	-cell function (19). Previous studies
have demonstrated that subjects with he-
patic insulin resistance have an increased
FPG concentration and impaired sup-
pression of hepatic glucose production
during the OGTT, resulting in an exces-
sive rise in plasma glucose concentration
at 30 and 60 min (20). In nondiabetic
subjects, the decline in plasma glucose
concentration at 30–60 min during the
OGTT is dependent on insulin sensitivity
in skeletal muscle and 	-cell function
(21,22). Thus, insulin resistance in liver
and skeletal muscle, as well as impaired
	-cell function, would result in an in-
crease in 1-h plasma glucose concentra-
tion. This renders the 1-h plasma glucose
a good indicator for the major metabolic
abnormalities that lead to the develop-
ment of type 2 diabetes. Consistent with
this, we previously demonstrated that the
plasma glucose concentration at 1 h dur-
ing the OGTT has a stronger correlation
with surrogate measures of hepatic and
muscle insulin resistance and 	-cell dys-
function compared with the 2-h plasma
glucose value (9).
In summary, the plasma glucose con-
centration at 1 h during the OGTT is a
strong predictor of future risk for type 2
diabetes. A cutoff point at 155 mg/dl plus
the ATP III criteria for the metabolic syn-
drome can be used to stratify nondiabetic
subjects into three risk groups—low, in-
termediate, and high risk—independent
of the 2-h plasma glucose concentration.
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